Anubis Somatropin 10 x 10 IU

What is somatropin?

Somatropin is the international generic name for recombinant human growth hormone (rhGH) — a protein molecule produced by genetic engineering that has an identical amino acid sequence to naturally occurring human growth hormone. The molecule consists of 191 amino acids in a continuous polypeptide chain with two intramolecular disulfide bridges, and has a molecular weight of approximately 22 kilodaltons. It is the product of the rhGH gene cloned into bacterial or mammalian cell systems (most commonly E. coli or mammalian cells); after expression, the protein is purified and freeze-dried into an injection-ready form.

Before recombinant technology became available in the 1980s, growth hormone was extracted from autopsy material—specifically, pituitary glands from deceased humans. That method was abandoned after a number of cases of Creutzfeldt-Jakob disease were linked to contaminated preparations. Genentech's Protropin, approved by the FDA in 1985, was the first commercially available recombinant variant (then in the form of methionyl-hGH with an extra methionine as the lead amino acid), and in 1987 the completely nature-identical 191-amino acid hormone was introduced under the trade name Humatrope from Eli Lilly.

Activity is traditionally expressed in international units (IU), where 1 mg of purified somatropin corresponds to approximately 3 IU. The 10×10 IU package is a standard pharmaceutical presentation: ten vials, each containing 10 IU reconstituted powder. The approved clinical indications include deficiency conditions in children (idiopathic growth hormone deficiency, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, short stature associated with chronic renal failure) as well as adult growth hormone deficiency as a result of pituitary pathology.

How does somatropin work?

After subcutaneous injection, somatropin is absorbed from the injection depot into the blood, with a bioavailability of around 70–80 percent and a plasma half-life of 2–4 hours. However, the biological half-life is significantly longer because the hormone primarily acts by inducing the formation of a secondary messenger hormone, IGF-1, whose levels persist in serum significantly longer than the administered somatropin.

At the cellular level, somatropin binds to the growth hormone receptor (GHR), a transmembrane protein receptor expressed on most tissues but in highest density in the liver. The binding triggers dimerization of two receptor molecules, which activates the intracellular kinase JAK2. JAK2 in turn phosphorylates the transcription factor STAT5b, which translocates to the cell nucleus and directs the transcription of target sequences — the IGF-1 gene being the central one. The liver is the major producer of circulating IGF-1, but many other tissues, particularly muscle, cartilage, and bone, locally produce IGF-1 that contributes to the paracrine effects.

Somatropin also has direct effects that are not mediated via IGF-1. The hormone is lipolytic — it stimulates the breakdown of triglycerides in adipose tissue via activation of hormone-sensitive lipase. Glucose metabolism is also directly affected: somatropin is insulin-antagonistic and can raise blood sugar with heavy exogenous supply, an effect central to the diabetogenic profile.

What can somatropin potentially affect?

In pharmacological literature from decades of clinical use in growth hormone deficiency as well as epidemiological research, several physiological systems return where somatropin leaves a clear imprint:

• Growth and linear height increase — in children with open epiphyses, somatropin via IGF-1 stimulates chondrogenesis in the growth zones and leads to increased linear growth rate.

• Protein metabolism — the nitrogen balance becomes positive, the synthesis of muscle protein increases and the breakdown decreases, both via direct influence and via IGF-1.

• Lipid metabolism — the hormone has a pronounced lipolytic effect, especially on visceral and subcutaneous fat, with a consequent decrease in total fat mass during prolonged treatment.

• Connective tissue and skin — collagen synthesis increases in skin, cartilage and tendons, a phenomenon documented in the treatment of adults with growth hormone deficiency.

• Glucose metabolism — insulin sensitivity may decrease and fasting blood glucose may rise, an effect that requires special attention in individuals with predisposing risk factors.

• Water and electrolyte balance — sodium and water retention is characteristic during the initial phase of treatment and explains phenomena such as peripheral edema and carpal tunnel symptoms.

Potential side effects of somatropin

The side effect profile of somatropin is well established from decades of clinical use in growth hormone deficiency and has also been extensively documented in epidemiological studies. The profile is dose-dependent — at replacement doses in GH-deficient patients, adverse effects are relatively rare, but at supraphysiological doses, the risk of several of the reactions below rises noticeably.

• Water and electrolyte balance — peripheral edema, facial edema, carpal tunnel syndrome due to fluid retention in the tissues surrounding nerve canals, and joint and muscle pain during the initial phase.

• Glucose metabolism — impaired insulin sensitivity, hyperglycemia and increased risk of developing type 2 diabetes, especially with prolonged exposure to high doses.

• Cardiovascular effects — left ventricular hypertrophy, increased blood pressure and edema are documented at supraphysiological exposure.

• Musculoskeletal — joint pain, muscle pain, stiffness of hands and joints, and risk of slippage of the epiphysis of the femoral head in children during growth.

• Tumor-related — the potential link between high IGF-1 levels and certain cancers (colorectal cancer, prostate cancer, breast cancer) is a key long-term concern that requires continuous monitoring in at-risk individuals.

• Local — redness, itching and lipoatrophy at the injection site, often mild and usually quickly transient.

The overall side effect picture of somatropin — fluid retention, glucose metabolic impact, IGF-1-mediated structural effects and theoretical tumor-related risk — means that clinical use requires close medical follow-up with laboratory controls (IGF-1 levels, fasting glucose, HbA1c, thyroid function) and individual assessment of the risk-benefit balance.